As a pharmacist, I'm asked almost daily whether Mounjaro is available on the NHS and, if not, what the private route through Mounjaro actually involves. Both routes exist, but they work quite differently. Understanding how each one operates can help you make a realistic decision, rather than being caught out by phased NHS access, local service arrangements or unclear eligibility criteria.
Table of Contents
1. What Is Mounjaro Licensed For?
2. Can You Get Mounjaro on the NHS?
3. What Are the Current Primary Care BMI and Health Criteria?
4. How Long Are NHS Waiting Times?
5. What About Private Prescriptions for Mounjaro?
6. NHS or Private: What Should You Consider?
7. A Note About Scotland, Wales and Northern Ireland
8. FAQs
8.1. Is Mounjaro free on the NHS?
8.2. What BMI do I need for Mounjaro on the NHS?
8.3. Can I get Mounjaro privately if I don't qualify on the NHS?
8.4. Why is NHS England primary-care access happening in stages rather than all at once?
What Is Mounjaro Licensed For?
Mounjaro (tirzepatide) is a prescription-only injectable medicine licensed in the UK for treating type 2 diabetes and, separately, for weight management. For weight management, it is licensed for adults with an initial BMI of 30 kg/m² or above or a BMI of 27 to below 30 kg/m² where at least one weight-related health condition is present. It is used alongside a reduced-calorie diet and increased physical activity.
Every route to treatment, whether NHS or private, requires an appropriate clinical assessment before prescribing. Mounjaro is not suitable for everyone and can cause side effects, so a prescriber should discuss the benefits, risks and monitoring requirements with you before treatment starts.
Can You Get Mounjaro on the NHS?
Yes. For weight management in England, there are two main NHS settings through which Mounjaro may be provided: specialist weight-management services and the phased primary-care pathway. These have different practical access criteria. Mounjaro also has a separate NHS treatment pathway for some adults with type 2 diabetes.
In specialist weight-management services, NICE TA1026 recommends tirzepatide for adults with an initial BMI of at least 35 kg/m² plus at least one weight-related comorbidity, where treatment is considered appropriate. NICE advises using a lower BMI threshold, usually reduced by 2.5 kg/m², for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds. NHS funding for eligible treatment through specialist services took effect from 24 March 2025, although local referral criteria, prioritisation and service capacity can still affect access.
Primary-care access is being introduced in phases. NHS England began funding this route from 23 June 2025, prioritising people with the greatest clinical need. The eligible population widened during 2026/27 under the planned rollout.
What Are the Current Primary Care BMI and Health Criteria?
As of August 2026, NHS England's first two primary-care cohorts are within the phased access programme. These are people with a BMI of 40 kg/m² or above and at least four qualifying comorbidities, and people with a BMI of 35 to 39.9 kg/m² and at least four qualifying comorbidities. The eligible primary-care population widened during 2026/27 to include Cohort II. NHS information has described this expansion as taking place from around June 2026, while the current commissioning guidance defines Cohort II by funding year rather than giving a single national start date.
The five qualifying comorbidities are type 2 diabetes mellitus, hypertension, dyslipidaemia, established atherosclerotic cardiovascular disease and obstructive sleep apnoea. NHS England uses specific clinical definitions for these conditions, so a diagnosis may need to meet the relevant criteria rather than simply appearing in your medical history. The relevant BMI thresholds are normally reduced by 2.5 kg/m² for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds.
How treatment is delivered can still vary locally. NHS England requires ICBs to have an approach for access to weight-management pharmacotherapy, but an individual GP practice may not necessarily prescribe tirzepatide itself. Local community, specialist or shared-care services may be used instead, and meeting the national eligibility criteria does not guarantee immediate treatment.
From 2026/27, NHS England incorporated primary-care management funding for weight-management pharmacotherapy into the Quality and Outcomes Framework (QOF). Two obesity-related indicators, OB004 and OB005, support referral to weight-management services and consideration of appropriate pharmacotherapy. This does not mean every GP practice will prescribe Mounjaro directly. ICBs can use different local delivery models, including general practice, community services, specialist outreach and shared-care arrangements, so the route through which an eligible patient receives treatment may vary locally.
If you meet the wider NICE criteria but not the current primary-care priority criteria, you can ask your GP whether referral to a specialist weight-management service is appropriate. However, specialist services can also apply local referral and prioritisation arrangements, and NHS England allows ICBs to align specialist-service prioritisation with the phased cohorting approach where necessary. Meeting the NICE criteria therefore does not guarantee immediate referral or treatment.
How Long Are NHS Waiting Times?
There is no single national waiting time for Mounjaro. Specialist weight-management waiting times depend on local referral criteria, prioritisation and service capacity. For primary care access, timing depends on the local pathway, whether your practice participates directly, clinical capacity and demand.
If you do not currently meet the criteria for a Mounjaro pathway, you may still be offered or referred for wider weight-management support, but this does not guarantee access to tirzepatide specifically.
What About Private Prescriptions for Mounjaro?
Private prescribing is not governed by NHS England's phased access cohorts. Private providers commonly use Mounjaro's licensed weight-management indication as the starting point for assessing eligibility: an initial BMI of 30 kg/m² or more, or 27 to below 30 kg/m² with at least one weight-related health condition. Individual providers and prescribers may apply additional clinical criteria, and meeting the BMI threshold does not automatically mean treatment is suitable.
A private consultation should include an appropriate review of your medical history, current medicines and relevant health conditions. For online services, current regulatory expectations also require appropriate verification, rather than relying solely on an unchecked questionnaire. Relevant information such as identity, BMI and clinical history should be appropriately verified before prescribing.
For more on the practical side of this, our article on accessing Mounjaro safely through trusted online sources covers what a legitimate private pathway should look like.
NHS or Private: What Should You Consider?
Neither route is automatically the right answer. The most suitable option depends on your BMI, health conditions, clinical suitability, local NHS access and whether you are considering private treatment. The comparison below reflects NHS England weight-management arrangements as of August 2026.
| Criteria | NHS specialist weight-management service — England | NHS primary care — England, August 2026 | Private route |
|---|---|---|---|
| Eligibility basis | NICE TA1026, with local referral and prioritisation arrangements | NHS England phased funding cohorts | Licensed indication plus individual provider/prescriber assessment |
| Current BMI threshold | 35 kg/m² or above | Cohort I: 40+; Cohort II: 35–39.9 | 30+, or 27–<30 with a weight-related comorbidity |
| Ethnicity adjustment | Usually reduce BMI threshold by 2.5 kg/m² for specified ethnic groups | Usually reduce BMI threshold by 2.5 kg/m² for specified ethnic groups | No equivalent NHS cohorting rule; individual clinical assessment applies |
| Health conditions required | At least 1 weight-related comorbidity | At least 4 of 5 specified qualifying comorbidities in current Cohorts I and II | At least 1 weight-related condition if BMI is 27–<30; additional provider criteria may apply |
| Who assesses you | Specialist weight-management pathway | GP/community/local pathway depending on local model | Appropriate regulated prescriber |
| Typical timing | Depends on local service capacity and prioritisation | Depends on local pathway, participation and capacity | Provider-dependent; not subject to NHS rollout queues, but prescribing only follows required clinical checks |
| Cost | NHS arrangements; prescription charges may apply in England | NHS arrangements; prescription charges may apply in England | Patient pays privately |
| Consultation required | Yes | Yes | Yes |
These are general patterns rather than guarantees. Local commissioning decisions, referral criteria, service capacity and individual clinical circumstances can all affect access. If you qualify for NHS treatment, you will not pay the private treatment price, although standard NHS prescription-charge rules apply in England where relevant.
If you do not currently meet the NHS England weight-management criteria, or you want to explore whether private treatment is clinically appropriate, a private consultation provides a separate route to assessment. A prescriber must still decide whether Mounjaro is suitable for you.
You may also want to compare Mounjaro with other treatment options, which our guide on Wegovy versus Mounjaro sets out in more detail, alongside further general information on our weight loss page.
If you'd like to find out whether Mounjaro could be suitable for you, you can start your consultation with our clinical team, who will assess your individual circumstances before anything is prescribed.
A Note About Scotland, Wales and Northern Ireland
This article describes NHS England access for weight management. NHS arrangements differ in Scotland, Wales and Northern Ireland. Scotland uses Scottish Medicines Consortium advice and local NHS Scotland pathways; Wales has its own national weight-management medication pathway, and Northern Ireland is introducing a Regional Obesity Management Service with separate phased eligibility. If you live outside England, check the current rules with your local NHS service.
Medical disclaimer: This article describes Mounjaro access for weight management through NHS England and private prescribing as of August 2026. NHS eligibility is being introduced in phases and may change, while local referral pathways, service capacity and GP-practice participation can also affect access. Different NHS arrangements apply in Scotland, Wales and Northern Ireland. This information is general and does not replace individual clinical advice. A qualified prescriber must assess whether Mounjaro is suitable for you before treatment is prescribed.
FAQs
Is Mounjaro free on the NHS?
If Mounjaro is prescribed to you through the NHS in England, you do not pay the private treatment price, although normal NHS prescription-charge rules apply where relevant. Eligibility for Mounjaro prescribed specifically for weight management follows the specialist service or phased primary care pathway. Separate NICE criteria apply when tirzepatide is prescribed for type 2 diabetes.
What BMI do I need for Mounjaro on the NHS?
For weight management in England, it depends on the setting. NICE's specialist-service threshold is generally BMI 35 kg/m² or above plus at least one weight-related comorbidity. Under the current primary-care rollout, Cohort I covers BMI 40 kg/m² or above plus at least four of the five qualifying comorbidities. During 2026/27, access widened to include Cohort II, covering BMI 35 to 39.9 kg/m² plus at least four qualifying comorbidities. Relevant BMI thresholds are usually reduced by 2.5 kg/m² for specified ethnic groups.
Can I get Mounjaro privately if I don't qualify on the NHS?
Potentially. Private prescribing is not restricted by NHS England's phased rollout cohorts and commonly starts from Mounjaro's licensed weight-management criteria: BMI 30 or above, or BMI 27 to below 30 with at least one weight-related health condition. A prescriber must still assess whether treatment is appropriate, and individual providers may apply additional clinical requirements.
Why is NHS England primary-care access happening in stages rather than all at once?
NHS England introduced primary-care access gradually to manage demand and capacity while prioritising people with the greatest clinical need. The eligible population


